Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Vasc Health Risk Manag ; 7: 433-43, 2011.
Article in English | MEDLINE | ID: mdl-21796258

ABSTRACT

The coexistence of depression and cardiovascular disease (CVD) is regularly discussed, and much debated. There is strong evidence that there are pathophysiological mechanisms, particularly endothelial dysfunction, altered platelet aggregation, and hyperactivation of the thrombosis cascade, which coexist with hypothalamic-pituitary-adrenocortical axis dysfunction, and link depression to CVD. Therefore, depression should not be automatically considered to be a consequence of life impairment due to myocardial infarction or major stroke. Probably, it should be considered as one of the many other stressful events, or "genetic reactions to life", which are risk factors for CVD development. This review will examine the significance of depression in clinical daily practice, its pathophysiology as a determinant in vascular events, and its real importance in, before, and after many CVD events.


Subject(s)
Cardiovascular Diseases/epidemiology , Depression/epidemiology , Antidepressive Agents/adverse effects , Cardiovascular Diseases/physiopathology , Cardiovascular Diseases/psychology , Comorbidity , Depression/drug therapy , Depression/physiopathology , Depression/psychology , Humans , Risk Assessment , Risk Factors
3.
J Cardiovasc Pharmacol ; 44(3): 401-6, 2004 Sep.
Article in English | MEDLINE | ID: mdl-15475840

ABSTRACT

Besides generating renal damage, hypertension plays an important role in the progression of diabetic nephropathy. The fructose-fed rat is a well-established model both of high blood pressure and renal impairment, which is similar to diabetic nephropathy. To clarify the relationship between hypertension, glucose metabolism, and kidney remodeling, we investigated the renal level of Glut 1 and Glut 5, their relation to fibrosis and the effects of an antihypertensive drug on renal damage. Twenty-four male WK rats were divided into three groups: 8 animals received a fructose-enriched diet, 8 a control diet, and 8 animals a high-fructose diet plus amlodipine (5 mg/Kg). After six weeks of treatment, we observed a significant increase in Glut 5, fibronectin, and sorbitol in fructose-fed rats compared with control and amlodipine-treated animals; there was a positive correlation between Glut 5 and fibronectin levels (r = 0.63). Glut 1 levels were similar in all three groups, whereas collagen IV was higher in fructose-fed rats; amlodipine prevented the increase of collagen IV and sorbitol. Collagen I was statistically higher in the fructose group than in the other two groups. Therefore, prolonged fructose feeding results in renal fibrosis via polyol pathway overactivity that can be prevented by means of an antihypertensive drug.


Subject(s)
Amlodipine/therapeutic use , Hypertension/drug therapy , Kidney Diseases/drug therapy , Polymers/metabolism , Administration, Oral , Amlodipine/administration & dosage , Amlodipine/pharmacokinetics , Animals , Blood Glucose , Blood Pressure/drug effects , Body Weight/drug effects , Collagen Type I/chemistry , Collagen Type I/metabolism , Collagen Type IV/antagonists & inhibitors , Collagen Type IV/chemistry , Collagen Type IV/metabolism , Diet , Disease Models, Animal , Fibronectins/antagonists & inhibitors , Fibronectins/chemistry , Fibronectins/metabolism , Fructose/administration & dosage , Fructose/adverse effects , Glucose Transporter Type 1 , Glucose Transporter Type 5 , Hypertension/chemically induced , Hypertension/complications , Immunohistochemistry/methods , Insulin/blood , Kidney/chemistry , Kidney/drug effects , Kidney/metabolism , Kidney Diseases/chemically induced , Kidney Diseases/complications , Male , Monosaccharide Transport Proteins/chemistry , Monosaccharide Transport Proteins/metabolism , Organ Size/drug effects , Polymers/adverse effects , Rats , Rats, Inbred WKY , Sorbitol/antagonists & inhibitors , Sorbitol/chemistry , Sorbitol/metabolism
4.
J Cardiovasc Pharmacol ; 42(6): 752-6, 2003 Dec.
Article in English | MEDLINE | ID: mdl-14639097

ABSTRACT

Previous studies have suggested that endothelins could be involved in the pathogenesis of target organ damage in diabetes. The aim of this study was to evaluate the possible protective effect of Bosentan, an antagonist of endothelin receptor, on the kidney of diabetic rats. The study comprised a control group of 10 WKY rats and a group of 22 WKY rats in which diabetes was induced by streptozotocin i.v.; 10 rats were the control group. Diabetic rats received insulin and mean blood glucose was approximately mS 400 mg/dl throughout the study; they were divided into two groups: 11 rats received Bosentan 100 mg/kg/die by gastric gavage and 11 received vehicle for 1 month. Twenty-four hour urine collection was performed before and at the end of the study. Urinary protein excretion rate was expressed as microg urinary protein/mg urinary creatinine. The renal collagen I, fibronectin, and TGFbeta were evaluated by means of immunochemistry. The statistical analysis of the results demonstrates that Bosentan has prevented the increase in urinary protein excretion and that of renal immunoreactive collagen I, fibronectin, and TGFbeta induced by diabetes without reducing blood pressure. This study suggests a new clinical application for the antagonists of endothelin receptors.


Subject(s)
Diabetes Mellitus, Experimental/complications , Diabetic Nephropathies/prevention & control , Endothelin Receptor Antagonists , Sulfonamides/therapeutic use , Animals , Blood Glucose/drug effects , Bosentan , Collagen/metabolism , Diabetic Nephropathies/etiology , Diabetic Nephropathies/metabolism , Fibronectins/metabolism , Kidney/drug effects , Kidney/metabolism , Rats , Rats, Inbred WKY , Transforming Growth Factor beta/metabolism
5.
Drugs ; 62(9): 1295-314, 2002.
Article in English | MEDLINE | ID: mdl-12076180

ABSTRACT

Resistance to the metabolic actions of insulin is thought to play a determining role in the aetiology of a great variety of disorders, including essential hypertension, accelerated atherosclerosis and cardiomyopathies. ACE inhibitors are recognised as being highly effective therapy for hypertension and cardiac insufficiency, and have a more beneficial effect on survival rate than expected on the basis of known mechanisms of action. The mechanism responsible for these extremely positive effects are just beginning to be understood and appear to be linked to the effects these drugs have on metabolism. The relationship between the insulin and angiotensin II (Ang II) signalling pathways needs to be fully clarified in order to prevent or correct the target organ damage resulting from changes in the cross-talk of these two hormonal systems. In recent years, Ang II has been shown to play a central role in cardiovascular and neuroendocrine physiology as well as in cellular cycle control. Moreover, the fact that Ang II utilises the insulin-receptor substrate (IRS)-1 to relay signals towards their intracellular destination, provides the biochemical explanation of how these two systems interact in a healthy organism and in a diseased one. Since it is overactivity of the renin-angiotensin system that seems to impair the intracellular response to insulin signalling, cardiovascular drugs that modulate the cellular transmission of Ang II have attracted particular interest. As well as the already widely-used ACE inhibitors, selective blockers of the Ang II type 1 receptor (AT(1)) have been shown to be clinically effective in the control of haemodynamic parameters, but with perhaps a less striking effect on glucose homeostasis. Many trials have investigated the effect of Ang II blockade on systemic glucose homeostasis. The inhibition of Ang II by ACE-inhibitors frequently showed a positive effect on glycaemia and insulin sensitivity, while information on the effects of AT(1) receptor antagonists on glucose homeostasis is more limited and controversial. An important limitation of these studies has been the short treatment and follow-up periods, even for the 'so called' long-term studies which were only 6 months. Several investigators have focused on the effects of the nuclear factors involved in gene transcriptions, especially with respect to the agonists/antagonists of peroxisome proliferator-activated receptors (PPARs) and their intriguing interconnections with the insulin and Ang II subcellular pathways. In fact, in vitro and in vivo experimental studies have shown that thiazolidinediones (selective PPAR-gamma ligands) are not only powerful insulin sensitisers, but also have anti-hypertensive and anti-atherosclerotic properties. In addition to conventional pharmacological approaches, attempts have been made to use genetic transfer in the treatment of cardiovascular and metabolic disorders. The development of powerful viral vectors carrying target genes has allowed us to restore the expression/function of specific proteins involved in the cellular mechanism of insulin resistance, and research now needs to move beyond animal models. Although a clearer picture is now emerging of the pathophysiological interaction between insulin and Ang II, especially from pre-clinical studies, there is much to be done before experimental findings can be used in daily clinical practice.


Subject(s)
Glucose/physiology , Heart Diseases/drug therapy , Heart Diseases/physiopathology , Heart/physiology , Homeostasis/physiology , Myocardium/metabolism , Renin-Angiotensin System/physiology , Animals , Diabetes Mellitus/genetics , Diabetes Mellitus/physiopathology , Glucose/metabolism , Heart/drug effects , Heart Diseases/genetics , Humans , Renin-Angiotensin System/drug effects
6.
J Mol Cell Cardiol ; 34(4): 389-400, 2002 Apr.
Article in English | MEDLINE | ID: mdl-11991729

ABSTRACT

The Na(+)/Ca(2+)-exchanger (NCX) is the main mechanism by which Ca(2+) is transported out of the ventricular myocyte. NCX levels are raised in failing human heart, and the consequences of this for excitation-contraction coupling are still debated. We have increased NCX levels in adult rabbit myocytes by adenovirally-mediated gene transfer and examined the effects on excitation-contraction coupling after 24 and 48 h. Infected myocytes were identified through expression of green fluorescent protein (GFP), transfected under a separate promoter on the same viral construct. Control experiments were done with both non-infected myocytes and those infected with adenovirus expressing GFP only. Contraction amplitude was markedly reduced in NCX-overexpressing myocytes at either time point, and neither increasing frequency nor raising extracellular Ca(2+) could reverse this depression. Resting membrane potential and action potential duration were largely unaffected by NCX overexpression, as was peak Ca(2+) entry via the L-type Ca(2+) channel. Systolic and diastolic Ca(2+) levels were significantly reduced, with peak systolic Ca(2+) in NCX-overexpressing myocytes lower than diastolic levels in control cells at 2 m m extracellular Ca(2+). Both cell relengthening and the decay of the Ca(2+) transient were significantly slowed. Sarcoplasmic reticulum (SR) Ca(2+) stores were completely depleted in a majority of myocytes, and remained so despite increasingly vigorous loading protocols. Depressed contractility following NCX overexpression is therefore related to decreased SR Ca(2+) stores and low diastolic Ca(2+) levels rather than reduced Ca(2+) entry.


Subject(s)
Myocardial Contraction/physiology , Sodium-Calcium Exchanger/physiology , Adenoviridae/genetics , Animals , Electrophysiologic Techniques, Cardiac , Genetic Vectors , Heart Ventricles , Male , Muscle Fibers, Skeletal , Rabbits , Sarcoplasmic Reticulum/metabolism , Sodium/metabolism , Sodium-Calcium Exchanger/biosynthesis
8.
Kidney Blood Press Res ; 25(6): 363-9, 2002.
Article in English | MEDLINE | ID: mdl-12590199

ABSTRACT

BACKGROUND: Early glomerular hypertrophy and late glomerulosclerosis have been observed in rats fed high fructose diet (HFD), comparable with those of diabetic rats. Several studies suggest a role for nitric oxide (NO) in the pathogenesis of renal damage in diabetes. This study investigated the possible role of NO in the pathogenesis of HFD-induced glomerular changes. METHODS: Three study protocols were adopted. In the first, 20 rats were divided into two groups to evaluate the effect of HFD on glomerular size and on the urinary excretion of NO. In the second, the glomerular size was evaluated in 40 rats divided into four groups receiving: (1) standard diet (SD); (2) HFD; (3) HFD + L-NAME, and (4) SD + L-NAME for 1 month. In the third, the renal expression of inducible enzyme (iNOS) was compared in 10 rats on HFD and in 10 controls after a 1-month diet. RESULTS: The results showed: (1) increased urinary excretion of NO and glomerular size, both induced by HFD; (2) prevention by L-NAME of the HFD-increased glomerular size, and (3) increased iNOS expression in the kidneys of rats fed HFD. CONCLUSION: These results suggest a role for NO in the pathogenesis of the early renal changes induced by HFD.


Subject(s)
Diabetic Nephropathies/metabolism , Diabetic Nephropathies/pathology , Fructose/pharmacology , Kidney Glomerulus/pathology , Nitric Oxide/metabolism , Animal Feed , Animals , Diabetic Nephropathies/etiology , Dietary Sucrose/pharmacology , Enzyme Inhibitors/pharmacology , Kidney Glomerulus/enzymology , Male , NG-Nitroarginine Methyl Ester/pharmacology , Nitric Oxide Synthase/metabolism , Nitric Oxide Synthase Type II , Rats , Rats, Inbred WKY
SELECTION OF CITATIONS
SEARCH DETAIL
...